Monday, 23 September 2019

AstraZeneca acquires Pearl Therapeutics

01 July 2013 | News | By BioSpectrum Bureau

AstraZeneca acquired 100 percent of Pearl Therapeutics' shares

AstraZeneca acquired 100 percent of Pearl Therapeutics' shares

Singapore: AstraZeneca has completed its acquisition of Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease.

Upon completion of the merger, AstraZeneca acquired 100 percent of Pearl's shares.

The acquisition gives AstraZeneca access to a potential new treatment for chronic obstructive pulmonary disease (COPD), currently in late-stage development, and inhaler and formulation technology that provides a platform for future combination products.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls